<PAGE>

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                                                   EXHIBIT 10.11

                              PHARSIGHT CORPORATION

                           DATA SET LICENSE AGREEMENT

This Data Set License Agreement (this "Agreement") is made and entered into as
of March 1, 2000 (the "Effective Date") by and between Pharsight Corporation, a
California corporation, (hereinafter "Pharsight") and the Lovelace Respiratory
Research Institute (hereinafter "Lovelace").

                                    RECITALS

Pharsight is engaged in the sale of software and services relating to clinical
trial design and modeling to pharmaceutical and biotechnology companies and
desires to have the right to use certain data sets developed by Lovelace both as
a data resource for an Internet-based query-response product and internally in
its professional consulting practice.

Lovelace is the owner of all rights to the data set necessary to carry out this
Agreement and is willing to grant to Pharsight a non-exclusive right and license
to use, reproduce, modify, and create derivatives of the subject data set on the
terms and conditions set forth herein.

NOW, THEREFORE, IN CONSIDERATION OF THESE PREMISES, AS WELL AS THE OBLIGATIONS
HEREIN MADE AND UNDERTAKEN, THE PARTIES HERETO DO HEREBY AGREE AS FOLLOW, WITH
THE CAPITALIZED TERMS HAVING THE MEANING SET FORTH IN APPENDIX A:


1. DATA SET DELIVERY, TESTING, AND UPDATES

1.1 DELIVERY OF INITIAL DATA SET. Lovelace will pool patient-level healthcare
data from the members of the Lovelace Data Consortium (the "Consortium") to
create the Data Set in accordance with the specifications in Appendix B and the
quality assurance procedures in Appendix C and will test the Data Set against
the Acceptance Criteria in Appendix D. As a first step, Lovelace will prepare
and deliver to Pharsight electronically within four (4) weeks of the Effective
Date a sample data set based on the Data Set that Pharsight can use for testing
and marketing purposes. The complete Data Set will be delivered within twelve
(12) weeks of the Effective Date.

1.2 ACCEPTANCE. Pharsight will have thirty (30) working days from receipt of the
Data Set to test for adherence to the Acceptance Criteria and will notify
Lovelace promptly if the Data Set fails to conform to such criteria. Lovelace
will have twenty (20) working days to correct such nonconformity, and upon
redelivery Pharsight will again test the Data Set against the Acceptance
Criteria. This process will be repeated (except that each subsequent test period
and repair period will be limited to fifteen (15) working days) until Pharsight
either provides Lovelace with written notice of acceptance of the Data Set or is
deemed to have accepted the Data Set under the provisions of this section,
provided, however, that if the Data Set fails to meet the Acceptance Criteria on
the third delivery, Pharsight shall have the right to terminate this Agreement
and receive a full refund of any royalty or license payments made to



[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.


                                       1
<PAGE>

Lovelace prior to such termination. Pharsight shall be deemed to have accepted
the Data Set if it fails to notify Lovelace of any nonconformity therein within
thirty (30) working days of delivery (or within fifteen (15) working days of
redelivery in the case of nonconformities in the original delivery).

1.3 PATIENT ANONYMITY. The Data Set will be totally anonymous as to the identity
of individual patients, the study, if any, in which those patients participated,
and the identity of medical practitioners and institutions providing treatment
and health plans covering treatment. Pharsight will not make any attempt to
ascertain such information or any other information that was rendered
confidential by substituting codes for identifying information before Lovelace
provided the Data Set to Pharsight. The parties will follow the confidentiality
protocol described in Appendix E hereto.

1.4 DATA ACCESS. Customers using the Product will have access only to summary
statistics presented in numeric, tabular, and graphical form. The Product will
be constructed so that it is not possible for Customers to access data records
for individual patients. Pharsight will maintain sufficient security measures,
including firewalls and secure transmission protocols, to ensure that patient
records from the Data Set are always under Pharsight's control and cannot be
accessed by its Customers. Pharsight will provide its consulting services
Customers with tabular, graphical, numerical or narrative results based upon
statistical analysis of data extracted from the Data Set by its own consultants.
All results provided to Customers will be in summary and non-patient specific
form, and Pharsight's consultants will not share data from individual patient
records in the Data Set with Customers unless required to do so by the FDA, in
which case Pharsight will notify Lovelace.

1.5 UPDATES. During the term of this Agreement, Lovelace will provide Pharsight
with an Update for the Data Set within thirty (30) days after the beginning of
each year of this Agreement (including any renewal terms). The Update will be
subject to quality assurance testing in accordance with the criteria established
by the parties.

1.6 COSTS. Lovelace will be fully responsible for all development and extraction
costs of the Data Set and any Updates, including any royalties or payments due
to third parties.


2. GRANT OF LICENSE

2.1 LICENSE GRANT FOR PRODUCT. Subject to the payment of royalties as set forth
in Section 4.2, Lovelace hereby grants Pharsight a world-wide right and license
(a) to use, reproduce, modify, and create derivatives of the Data Set and
Documentation internally for development of the Product; (b) to license the
Product to its Customers; (c) to license its Customers to use results obtained
through the use of the Product for research in support of therapeutic innovation
in drug development and related marketing activities, including regulatory
submissions and research publications; (d) to use the Data Set and the
Documentation for purposes of technical support for Customers; (e) to use a
reasonable number of copies of the Product and Data Set for purposes of
marketing, training, and demonstrations.

2.2 LICENSE GRANT FOR CONSULTING. Pharsight will have unrestricted access to the
Data Set for use in its consulting activities related to research in support of
therapeutic innovation in drug development and related marketing activities and,
subject to the royalty obligations of Section 4.3 and the confidentiality
clauses of Appendix E, Lovelace hereby grants Pharsight a world-wide right and
license (a) to use the Data Set and Documentation to prepare statistical results
and conclusions based on the Data Set under consulting contracts with Customers;
(b) to distribute to such Customers models, other analyses, and



[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.


                                       2
<PAGE>

conclusions based on its analysis of the data in the Data Set; and (c) to allow
such Customers to use such models, analyses, and conclusions for drug
development and related marketing activities, including regulatory submissions
and research publications. Pharsight will provide Lovelace with an anonymized
summary list of the types of analyses performed for Customers every six months.

2.3 OWNERSHIP. Lovelace will retain ownership of the Data Set and the underlying
data. Pharsight will own all right, title, and interest in and to the query,
user interface, and other software developed by or for Pharsight as part of the
Product, as well as all models and analyses created for Customers as part of its
consulting activities.

2.4 LIMITED EXCLUSIVITY. During the term of this Agreement, Lovelace will not
sell or license the Data Set or any other data set from the Consortium to any
third party for use in or development of Internet-based software systems related
to clinical drug development or for providing services related to clinical trial
simulation or clinical drug development in the biopharmaceutical industry.


3. PRODUCT DEVELOPMENT, MARKETING AND DISTRIBUTION

3.1 PRODUCT DEVELOPMENT. Pharsight will develop the query, user interface, and
other software for the Product that will allow licensed Customers to access the
information in the Data Set, as described in the application overview in
Appendix B. The target date for commercial release of the Product is June 2000.

3.2 PRODUCT MARKETING ACTIVITIES. Pharsight will be responsible for all
decisions and costs involved in the marketing and distribution of the Product
and consulting services utilizing the Data Set, including pricing, end-user
license terms, promotional materials, packaging, distribution channels, and
customer evaluation and training. Pharsight may distribute the Product through
Distributors so long as such Distributors have no direct access to the Data Set.
Pharsight may authorize its Distributors to use the Product for marketing,
training, and demonstrations.

3.3 DATA SET SOURCE IDENTIFICATION. Pharsight may identify the Data Set as
having been prepared by Lovelace, but will not represent that use of the Data
Set represents any endorsement of the Pharsight product by Lovelace or any
member of the consortium. Pharsight agrees to adhere to the organizational
confidentiality clauses stipulated in Appendix E. Any marketing materials
containing references to Lovelace other than identification of the source of the
Data Set, as set forth in Appendix E, will be submitted to Lovelace (to the
attention of Patricia J. Marx, Chief Operating Officer, via certified mail) for
advance approval at least thirty (30) days prior to their intended use. Lovelace
shall be deemed to have approved the marketing materials if it fails to notify
Pharsight of any problems therein within thirty (30) days of submission.

3.4 CUSTOMER SUPPORT. Pharsight will provide customer support for the Product.
Lovelace will make one or more persons familiar with the Data Set available to
assist Pharsight personnel in the resolution of problems they may encounter from
time to time in use of the Data Set. For each [ * ] in royalties paid by
Pharsight to Lovelace (including the annual license fee), Lovelace will provide
one day of problem resolution assistance to Pharsight personnel without charge;
further assistance will be provided as reasonably necessary at [ * ] per day,
prorated on an hourly basis for usage of less than a full day.



[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.


                                       3
<PAGE>

3.5 PRESS ANNOUNCEMENTS. Pharsight will issue a press release announcing the
relationship between Pharsight and Lovelace (target release date: March 28,
2000), which announcement shall be subject to approval by Lovelace and subject
to Sections 3.2, 3.3 and Appendix E. Lovelace agrees that it will supply a
quotation for the press release. The parties agree that as further news about
the relationship is generated in the future, they will cooperate with each other
to issue appropriate press releases to cover such news.


4. PAYMENTS

4.1 ANNUAL LICENSE FEE. To allow Lovelace to cover up-front expenses associated
with the preparation of the Data Set, Pharsight will make a lump-sum, minimum
royalty payment to Lovelace as follows: (a) [ * ] upon execution of this
Agreement and (b) [ * ] upon delivery of the Data Set. To cover the up-front
expenses for creating the Updates, Pharsight will make lump-sum, minimum royalty
payments to Lovelace as follows: (a) [ * ] at the start of each subsequent year
of this Agreement (including renewal terms); and (b) [ * ] upon the delivery of
the Updates in accordance with Section 1.5. These non-refundable payments will
be credited against actual royalties due in each year under Section 4.2 and 4.3
below. Should the royalties due under Sections 4.2 and 4.3 for a year be less
than these minimum payments, then Lovelace shall be entitled to retain the full
minimum payment.

4.2 PRODUCT ROYALTY. Pharsight will pay Lovelace a royalty of [ * ] for each
annual Customer subscription license allowing use of the Product. No royalty
will be due for evaluation licenses allowing a Customer limited use of the
Product, provided Pharsight receives no revenue for such evaluation licenses, or
for use of the Product in Customer training programs.

4.3 SERVICE USE ROYALTY. Pharsight will pay Lovelace a royalty of [ * ] for each
Customer project for which Pharsight's staff accesses the Data Set in connection
with providing consulting services to the Customer. No royalty will be due for
use of the Data Set for Pharsight staff training.

4.4 PAYMENTS. Royalty payments will be made on a quarterly basis with payment
due thirty (30) days after the end of each calendar quarter for all Product
license revenue received during such quarter and all consulting service revenue
recognizable (under generally accepted accounting principles) during such
quarter. Each payment will be accompanied by a report setting forth the
calculation of such payment amount.

4.5 DELIVERY BONUS. Should Lovelace deliver the Data Set meeting the
Acceptance Criteria to Pharsight by May 15, 2000, Lovelace shall receive a
Delivery Bonus of [ * ]. Should Lovelace deliver the Data Set meeting the
Acceptance Criteria to Pharsight by April 30, 2000, Lovelace shall receive a
Delivery Bonus of [ * ]. The Delivery Bonus is a one-time payment and need
not be credited against any other royalty payments.

4.6 ADDITIONAL CONSORTIUM MEMBERS. For additional Consortium members in excess
of three (3) members, up to and including six (6) members, Lovelace will receive
the following payment increases: (a) the minimum annual royalty in Section 4.1
will be increased by [ * ] per new member to a maximum of [ * ], with [ * ] paid
at signing or renewal of the Agreement, and [ * ] paid at delivery of the Data
Set or Updates; (b) the product royalty in Section 4.2 will be increased by [ *
] per new member to a maximum of [ * ]; and (c) the service use royalty in
Section 4.3 will be increased by [ * ] per new member to a maximum of [ * ].
These increased payments will apply only to minimum annual royalties,



[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.


                                       4
<PAGE>

annual Customer subscription license royalties, or Customer consulting project
royalties accrued after the Data Set has been contributed to by such added
Consortium member(s).

4.7 AUDIT. Pharsight will, upon written request, during normal business hours,
but not more frequently than once each calendar year, provide access for
purposes of audit to pertinent records relating to royalties payable in
connection with the Data Set to an independent accounting firm chosen and
compensated (other than on a contingent fee basis) by Lovelace and reasonably
acceptable to Pharsight. Such accounting firm will be authorized to report to
Lovelace only the amount of royalties due and payable for the period examined.
If the amount under-reported by Pharsight is equal to or greater than ten
percent (10%) of the total payment due to Lovelace for the payment period so
audited, then the cost of the audit shall be borne by Pharsight.

4.8 CONFIDENTIALITY. Lovelace will not disclose to any third party any sales or
customer information received from Pharsight in connection with royalty payments
and will use such information solely for the purpose of carrying out its
obligations under this Agreement.


5. WARRANTIES; INDEMNIFICATION; LIMITATION OF LIABILITY

5.1 WARRANTY. Lovelace represents and warrants to Pharsight (a) that Lovelace
will obtain prior to delivery of the Data Set, all rights and authority
necessary for the grant of rights and licenses pertaining to this Agreement; (b)
that the Data Set as supplied to Pharsight will be developed in substantial
accordance with the quality assurance procedures described in Appendix C for
generating and validating the data; (c) that no consents are required to use and
redistribute the data in the Data Set as authorized in this Agreement; and (d)
that agreements between Lovelace and the Consortium to use and redistribute the
data in the Data Set will be obtained prior to delivery of the Data Set and will
be available for review by Pharsight. If Pharsight is required to cancel any
Customer license for the Product because of Lovelace's breach of one of the
foregoing warranties, Lovelace will refund to Pharsight any royalties paid with
respect to such cancelled licenses.

5.2 INDEMNIFICATION. Pharsight will defend, indemnify, and hold Lovelace
harmless from and against any action or other proceeding brought against
Lovelace arising from Pharsight's use of the Data Set, except where such action
arises from negligence or willful misconduct on the part of Lovelace or from
Lovelace's breach of the representations and warranties set forth in Section
5.1. Lovelace will defend, indemnify, and hold Pharsight harmless from and
against any action or other proceeding brought against Pharsight to the extent
that it is based on (i) Lovelace's negligence or willful misconduct; (ii) a
claim that any part of the Data Set or Documentation infringes any copyright or
patent or incorporates any misappropriated trade secrets of any third party; or
(iii) a claim that use or distribution of the Data Set as authorized herein
violates federal or state patient-privacy laws or regulations or the privacy
rights of any patient included in the Data Set as such laws were in effect at
the time of delivery of the version of the Data Set that is the subject of such
claim.

5.3 CONDITIONS OF INDEMNIFICATION. The indemnifying party will pay any and all
costs, damages, and expenses (including but not limited to reasonable attorneys'
fees) incurred by the indemnified party in any action or proceeding requiring
indemnification under section 5.2 (an "Action"). The indemnifying party will
have no obligation as to any Action unless (i) the indemnified party gives it
prompt notice of the Action; (ii) the indemnifying party has sole control of the
defense and settlement of the Action; and



[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.


                                       5
<PAGE>

(iii) the indemnified party provides the indemnifying party, at the indemnifying
party's expense, with reasonable assistance in defense and settlement of the
Action.

5.4 LIMITATION ON LIABILITY. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE
OTHER FOR ANY INDIRECT, CONSEQUENTIAL, SPECIAL OR INCIDENTAL DAMAGES (INCLUDING
DAMAGES FOR LOSS OF BUSINESS PROFITS, BUSINESS INTERRUPTION, LOSS OF BUSINESS
INFORMATION, AND THE LIKE) ARISING OUT OF THIS AGREEMENT EVEN IF SUCH PARTY HAS
BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. EXCEPT WITH RESPECT TO THE
INDEMNIFICATION OBLIGATIONS UNDER SECTIONS 5.2 AND 5.3, NEITHER PARTY'S
LIABILITY UNDER THIS AGREEMENT SHALL EXCEED THE AMOUNTS PAID TO LOVELACE UNDER
THIS AGREEMENT. BOTH PARTIES ACKNOWLEDGE THAT THE FOREGOING LIMITATION REFLECTS
A BARGAINED-FOR ALLOCATION OF RISK AND THAT THE ROYALTIES SET FORTH HEREIN
REFLECT SUCH RISK.


6.  TERM AND TERMINATION

6.1 TERM OF AGREEMENT. The initial term of this Agreement will be the period
beginning on the Effective Date of this Agreement and ending on the first
anniversary of the date on which Pharsight accepts (in accordance with Section
1.2) the Data Set. This Agreement may be renewed for two successive additional
one-year periods at Pharsight's option and beyond that may be renewed by mutual
agreement of the parties.

6.2 TERMINATION FOR NON-DELIVERY. If Lovelace fails to deliver the Data Set in a
form meeting the Acceptance Criteria within six (6) months of the Effective
Date, then Pharsight shall have the option to terminate this Agreement, return
any copies of the Data Set in its possession, and receive from Lovelace a refund
of any royalty or license payments made to Lovelace prior to such termination.
If Lovelace fails to deliver an Update meeting the Acceptance Criteria within
sixty (60) days of the start of the renewal term, then Pharsight shall have the
option to terminate this Agreement, return any copies of the Data Set in its
possession, and receive from Lovelace a refund of any royalty or license
payments made to Lovelace with respect to such renewal term prior to such
termination.

6.3 TERMINATION FOR BREACH. Each party has the right to terminate this Agreement
if the other party has materially breached any obligation herein and such breach
remains uncured for a period of thirty (30) days after written notice thereof is
sent to the other party.

6.4 LOSS OF DATA ACCESS. In the event that at any time during the term of this
Agreement there is a period of at least sixty (60) days in which the number of
Consortium members having access to data to contribute to the Data Set is less
than three (3), Lovelace shall so notify Pharsight and shall thereafter have no
obligation to provide Updates. Pharsight's rights with respect to the Data Set
shall continue for one year from the date of such notice, but the royalties due
under Sections 4.2 and 4.3 shall be reduced to fifty percent (50%) of the amount
set forth in such sections during such one-year period.

6.5 EFFECT OF TERMINATION. Upon termination or expiration of this Agreement, all
rights and licenses granted to Pharsight hereunder shall terminate. Termination
will have no effect on the rights of any Customer to continue to use the Product
or any information obtained from the Data Set or Product prior to such
termination in accordance with its original license for the Product or grant of
rights from Pharsight with respect to consulting services deliverables.
Notwithstanding any termination of this



[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.


                                       6
<PAGE>

Agreement, Lovelace shall remain entitled to royalties owed pursuant to this
Agreement resulting from use or license of the Data Set or Product prior to
termination of this Agreement.

6.6 SURVIVAL. The provisions of Sections 2.3, 3.3, 4.7, 4.8, 5, 6.5, 6.6, 8, and
9 will survive any termination or expiration of this Agreement.


7. ADDITIONAL DATA SETS

If Pharsight identifies other therapeutic areas where Pharsight wishes to
license a data set for its Internet query-response product and consulting use,
Pharsight will propose specifications for data set development to Lovelace.
Lovelace will respond within sixty (60) days, and if Lovelace agrees that the
proposed data set is practicable to develop, the parties will then work together
to finalize the specifications. At the time such specifications are agreed upon
for a given data set, the parties will enter into an agreement similar to this
Agreement setting forth the provisions for delivery, quality assurance testing,
and licensing terms. The royalty provisions for any additional data set in any
such agreement that is entered into during the term of this Agreement will be
the same as those in this Agreement.


8. MEDIATION AND ARBITRATION

8.1 MEDIATION. Any dispute arising under this Agreement will be resolved through
a mediation and arbitration approach. The parties agree to select a mutually
agreeable, neutral third party to help them mediate any dispute that arises
under the terms of this Agreement. Costs and fees associated with the mediation
will be shared equally by the parties.

8.2 ARBITRATION. If the mediation is unsuccessful, the parties agree that the
dispute will be decided by binding arbitration under the rules of the American
Arbitration Association. The decision of the arbitrators will be final and
binding on the parties and may be entered and enforced in any court of competent
jurisdiction by either party. The prevailing party in the arbitration
proceedings will be awarded reasonable attorney fees, expert witness costs and
expenses, and all other reasonable costs and expenses incurred in connection
with the proceedings, unless the arbitrators for good cause determine otherwise.


9. GENERAL

9.1 NOTICES. Any notice required or permitted hereunder must be in writing, and
will be effective on the date of delivery when delivered personally, the next
business day after dispatch when sent by Federal Express or other recognized
overnight courier service, or the fifth business day after dispatch when sent by
certified mail, postage prepaid, return receipt requested. Notices should be
addressed to the other party at the address shown below or at such other address
as a party may designate by ten days' advance written notice to the other party:

 Pharsight Corporation                   Lovelace Respiratory Research Institute
 800 West El Camino Real, Suite 200      P.O. Box 5890
 Mountain View, CA  94040                Albuquerque, NM 87185-5890
 Attention:  Chief Financial Officer     Attention: Patricia J. Marx,



[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.


                                       7
<PAGE>

 Phone: (650) 314-3800                   Chief Operating Officer
 Fax: (650) 314-3810                     Phone:  (505) 845-1193
                                         Fax:   (505) 845-1067

9.2 ENTIRE AGREEMENT; MODIFICATIONS. This Agreement, including all appendices,
constitutes the entire agreement of the parties with respect to the subject
matter hereof and supersedes all prior representations, proposals, discussions,
and communications, whether oral or in writing. This Agreement may be modified
or amended only by a writing executed by a duly authorized representative of
each party.

9.3 FORCE MAJEURE. Neither party will be liable to the other for any failure or
delay caused by events beyond such party's control, including, without
limitation, sabotage, riots, insurrections, fires, flood, storm, explosions,
war, or earthquakes. However, if such events shall continue for thirty (30) days
or more, the other party shall have the option of terminating this Agreement by
giving written notice of termination.

9.4 CHANGE IN LAW; CHANGE IN CIRCUMSTANCES. No party shall make or receive any
payment or take any action under this Agreement if any judicial decision,
legislative action, or regulatory or other administrative interpretation,
whether federal or state, would render illegal the conduct of either party under
this Agreement. If performance by either party of any term of this Agreement
should be deemed illegal by any party or third party who is essential to
performance of this Agreement for any such reason, either party shall have the
right to require that the other party renegotiate the terms of this Agreement.
If the parties fail to reach an agreement satisfactory to both parties within
fifteen (15) days after the receipt of any request for renegotiation, either
party may terminate this Agreement upon ten (10) days prior written notice to
the other party, or sooner if required by law.

9.5 ASSIGNMENT. This Agreement will be binding upon and inure to the benefit of
the parties hereto, their successors and permitted assigns. Either party may
assign this Agreement in its entirety to a successor corporation upon notice to
the other party in the event of a merger or an acquisition of all or
substantially all of the assets of the assigning party.

9.6 GOVERNING LAW. All questions concerning the validity, operation,
interpretation, and construction of this Agreement will be governed by and
determined in accordance with the laws of the State of New Mexico, without
regard to its conflict of laws provisions. Application of the United Nations
Convention on Contracts for the International Sale of Goods is specifically
excluded.

9.7 SEVERABILITY. If a court of competent jurisdiction determines that any
provision of this Agreement is invalid, illegal, or otherwise unenforceable,
such provision shall be replaced with a valid, enforceable provision as nearly
as possible in accordance with the stated intention of the parties, while the
remainder of this Agreement shall remain in full force and effect. To the extent
any provision cannot be enforced in accordance with the stated intentions of the
parties, such provision shall be deemed not to be a part of this Agreement.

9.8 COUNTERPARTS. This Agreement may be executed in any number of counterparts,
all of which together will constitute one and the same instrument.



[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.


                                       8
<PAGE>

IN WITNESS THEREOF, THE PARTIES HAVE CAUSED THIS AGREEMENT TO BE EXECUTED BY
THEIR RESPECTIVE DULY AUTHORIZED REPRESENTATIVES AS SET FORTH BELOW:

PHARSIGHT CORPORATION                  LOVELACE RESPIRATORY RESEARCH INSTITUTE

By: /s/ ROBIN KEHOE                    By:   /s/ PATRICIA J. MARX
   ----------------------------            ------------------------------------
Robin A. Kehoe                         Name:  Patricia J. Marx
Chief Financial Officer                Title:  Chief Operating Officer







[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.


                                       9
<PAGE>



                                   APPENDIX A

                                   DEFINITIONS

DATA SET means the anonymized database in the diabetes therapeutic area
described in Appendix B and all Updates when and as delivered to Pharsight.

DOCUMENTATION means any and all materials provided to Pharsight by Lovelace
describing the features, structure, functions, fields, contents, collection
methods, etc. of the Data Set.

CUSTOMER means a customer of Pharsight or of its distributors to whom Pharsight
has licensed the use of the Product or to whom Pharsight has provided consulting
services utilizing the Data Set.

ACCEPTANCE CRITERIA means the specifications for the Data Set set forth in
Appendix B and the quality requirements for the Data Set set forth in Appendix D
or otherwise agreed upon in writing by the parties.

PRODUCT means Pharsight's Internet query-response product, and all updates,
upgrades, and new versions thereof, utilizing the Data Set or any Updates.

DISTRIBUTOR means a third-party sales and marketing organization contracted by
Pharsight to market and sell Product subscriptions in selected geographic
regions or market segments.

UPDATE means a new version of the Data Set, consisting of a new statistical
extraction made from the most recent provider database according to the
specifications defined in Appendix B.





[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.


                                       10
<PAGE>



                                   APPENDIX B

               SPECIFICATION AND APPLICATION FOR INITIAL DATA SET

APPLICATION OVERVIEW

The Data Set is intended for use with the Pharsight Internet query-response
system, which 1) allows users to ask detailed drug development questions, 2)
acts as an intelligent interface to find and extract the relevant information
from the database, 3) performs relevant numerical analysis to produce summary
results, and 4) presents the aggregate results to the users via lists, graphs
and plots. Typical question areas include incidence and statistical
distributions of specific patient characteristics in anonymous patient databases
and determination of the time course of medical condition and status in both
normal aging and pathological disease states. The system and its methods produce
reports that can be used to improve the process of developing new medical
therapeutics, including new drugs, drug delivery systems, and medical devices
and supplies. The system uses secure Internet technology, allowing users to
access the system 24-hours/day.

OUTLINE OF SPECIFICATIONS FOR DATA SET

DIABETES DATA SET SPECIFICATIONS

1. Diabetes patients will be identified as follows: During the calendar years
[ * ], select all [ * ] patients with 1) at least [ * ] outpatient visits coded
as [ * ] or 2) [ * ] hospital admission coded as [ * ], or 3) [ * ] or more
[ * ]. The date [ * ] on which each patient first meets the diabetes eligibility
criteria shall be their [ * ].

2. Those diabetes patients who have [ * ] in their files [ * ] will be excluded
from the sample.

3. The following data will be extracted for the [ * ]

I. ENROLLMENT [ * ]
Anonymized, unique patient ID number
[ * ]
II. DEMOGRAPHICS [ * ]
Anonymized, unique patient ID number
Year of birth
Sex
[ * ]
III. [ * ]
Anonymized, unique patient ID number
[ * ]

IV.  [ * ]
Anonymized patient ID number

[ * ]

[ * ]
Anonymized patient ID number




[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.



                                       11
<PAGE>

[ * ]
Anonymized patient ID number
[ * ]

FILE FORMAT: The data shall be provided to Pharsight in the form of ascii files,
with multiple files or tables acceptable [ * ]. If multiple files are provided,
all individual patient records shall be linkable across all files by a common
encrypted patient identification number.

DATA SETS IN OTHER THERAPEUTIC AREAS
Should the Lovelace Data Consortium agree to provide databases to Pharsight
Corporation in additional therapeutic areas, the data elements to be provided
shall be substantively the same as those described above for the Diabetes Data;
however, a different, mutually agreed upon algorithm appropriate to the
therapeutic area will be used for identifying patients and laboratory values to
be provided will be relevant to the therapeutic area.





[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.


                                       12
<PAGE>


                                   APPENDIX C

                      DATABASE QUALITY ASSURANCE PROCEDURES

For the purposes of this Appendix C, the variable "X" as it appears below is to
be determined and agreed upon by the parties at a later date. Before providing
the Data to Pharsight, Lovelace will perform the following quality assurance
procedures:

1)   UNIQUENESS OF PATIENT IDENTIFIERS: Data across all [ * ] plans/panels will
     be sorted to ensure there is no duplication of patient identifiers.

2)   ACCURACY OF GENDER: Selected procedures that are sex-specific will be
     tested to ensure the sex variable is correct in X% of cases (for example,
     files will be checked to ensure no pregnancy or pelvic exam procedures
     occur in males). If more than X% of records appear to be incorrect, the
     contributing organization will be asked to investigate their demographic
     files for a systematic or programming error. If indicated, the contributing
     organization will be asked to re-extract their demographic data.

3)   COMPLETENESS OF FILES: A count will be performed to determine if the number
     of records is consistent from month to month for a given plan/panel. This
     process will help ensure that no large blocks of records are missing. Total
     number of records per month will be counted for: [ * ]. Some seasonal
     variation in health care utilization can be anticipated; however if a
     discrepancy of more than X% from month to month in a given category [ * ]
     is found, the contributing organization will be asked to verify
     completeness of the files. If indicated, the contributing organization will
     be asked to re-extract their data set or to supply a patch file to Lovelace
     containing the missing data.

4)   COMPLETENESS OF INDIVIDUAL RECORDS: For the [ * ] categories of health care
     utilization, the total number of missing fields will be counted to
     ascertain completeness of individual encounter records. If more than X% of
     records are missing one or more data elements (an example would be a [ * ]
     record that is missing the [ * ] variable), an investigation will be
     conducted to ascertain whether this is due to a systematic programming or
     extraction error or due to incomplete data entry/capture at the source
     (which cannot be corrected). If due to a programming/extraction error, the
     error will be [ * ].

5)   COMPLETENESS OF LABORATORY RECORDS: The ratio of lab procedures to [ * ]
     will be computed for each [ * ] for each plan/panel. A variation of more
     than X will be investigated to ensure that all laboratory records have been
     captured.

6)   UNIQUENESS OF LABORATORY RECORDS: To eliminate duplication of laboratory
     outcomes records, laboratory results reported both as part of a panel
     report and as an individual result will be collapsed into one record. To do
     this, any laboratory records for the same test, done on the same day, and
     reporting the exact same result will be collapsed into one record.

7)   QUALITY ASSURANCE CHECKLIST: A Quality Assurance checklist will be
     submitted to Pharsight. The checklist will contain summaries of the
     investigations and counts described in items 1-5 above.



[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.


                                       13
<PAGE>



                                   APPENDIX D

                               ACCEPTANCE CRITERIA

1.   A completed Quality Assurance Checklist (as stipulated in Appendix C) is
     received from Lovelace with the delivered Data package.

2.   The Quality Assurance Checklist indicates the Data conforms to the criteria
     outlined in Appendix C, Quality Assurance Procedures

3.   The Data contains the following content files:

         [ * ]


4.   The Data contain the individual data elements described in Appendix B.

5.   The Data package contains the following dictionaries:

         [ * ]


6.   The Data package contains a text file describing the contents and structure
     of the delivered Data files (a "ReadMe" file).




[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.


                                       14
<PAGE>


                                   APPENDIX E

                            CONFIDENTIALITY PROTOCOL

The purpose of this confidentiality protocol is to describe the means by which
patient and organizational confidentiality will be protected during the term of
Lovelace's agreement with Pharsight.

I.   PROTECTION OF PATIENT CONFIDENTIALITY

A.   Data Transfer from Lovelace to Pharsight

1.   Data provided to Pharsight will be stripped of any patient identifiers
     before the Data is shipped to Pharsight. These patient identifiers include:

-    Name
-    Home address, including street number, building name, apartment number,
     city and zip code
-    Home phone number
-    Medical record number
-    Plan ID number
-    Plan guarantor ID number
-    Social security number
-    Complete birth date
-    Physician name (primary care or other physician)
-    Physician address
-    Physician phone number
-    Employer group or name
-    Work address
-    Work phone number
-    Any other identifier identified by the contributing organization

-    [ * ]

3.   If Pharsight inadvertently receives a data file that contains any of the
     identifying information listed in item 1 above, the Pharsight staff person
     working with the file will:

-    Immediately note the location of the electronic file(s)
-    Delete any electronic copies of the record(s) from Pharsight computers,
     floppy disks or tapes
-    Shred any hard copies of the file output
-    Provide written notification to Lovelace describing the identifying file
     information
-    Place written documentation of the incident in Pharsight files


II.  PROTECTION OF ORGANIZATIONAL CONFIDENTIALITY

A.   The merged data file provided by Lovelace to Pharsight will contain no data
     element(s) that can be used to identify the organization that contributed
     the data for a given patient or group of patients.



[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.


                                       15
<PAGE>

B.   In its marketing, client consulting activities, or other activities,
     Pharsight will be prohibited from divulging the names of the contributing
     organizations, except when given prior written authorization by the
     appropriate Consortium member.

C.   Pharsight may describe the source of the Data as follows

         "The health care data which underlie the Pharsight (PRODUCT/CONSULTING
         SERVICE) are derived from three health care organizations that are
         members of the Lovelace Data Consortium. This Consortium was created
         and is managed by the Southwest Center for Managed Care Research of the
         Lovelace Respiratory Research Institute. The patient-level data from
         these three organizations have been merged into one combined database.
         One of the contributing organizations is a managed care organization in
         the southwestern United States. The second organization is a provider
         group with a capitated outpatient population in the southwestern United
         States. The third organization is a network model managed health care
         plan in the mid-Atlantic region of the United States."

In addition to using the above language as a whole, Pharsight may alternatively
use the first two sentences alone or the first three sentences alone. Any other
wording that Pharsight uses to describe the source of the Data must first be
approved by Lovelace in writing in accordance with Section 3.3.



[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.


                                       16